I think I agree with that. I don't purport to have expertise in this, but I was a provincial cabinet minister at one point in my life and I'm familiar with some of the difficulties.
I think the problem now is that the industry plays provinces off each other. I'm sure you're aware of that from your own health care background. If we're going to have a sufficiently efficient system through which we can also address the issues that Janet Yale raised, obviously when there's a very effective drug for someone with a devastating disease, all of us would like to see that drug being affordable for that person. The treatment with an effective drug may be more important than the visits to the doctor. In fact, undoubtedly they are, but the drug has to be affordable. Professor Coyle made this point nicely with the example of Soliris, which is an extreme one. I would strongly recommend that you review Kelly Crowe's report on CBC television. You should review it at least twice, because the report points out that the real cost of developing that drug was virtually nothing, possibly less than 1% of its present sales price.